Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Accounts Payables: 2011-2024

Historic Accounts Payables for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to $3.3 million.

  • Capricor Therapeutics' Accounts Payables fell 58.36% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 58.36%. This contributed to the annual value of $3.3 million for FY2024, which is 47.46% down from last year.
  • Latest data reveals that Capricor Therapeutics reported Accounts Payables of $3.3 million as of FY2024, which was down 47.46% from $6.3 million recorded in FY2023.
  • Capricor Therapeutics' Accounts Payables' 5-year high stood at $6.3 million during FY2023, with a 5-year trough of $2.7 million in FY2020.
  • Its 3-year average for Accounts Payables is $4.8 million, with a median of $4.8 million in 2022.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 202.41% in 2020, then slumped by 47.46% in 2024.
  • Capricor Therapeutics' Accounts Payables (Yearly) stood at $2.7 million in 2020, then rose by 14.76% to $3.1 million in 2021, then soared by 55.14% to $4.8 million in 2022, then rose by 29.28% to $6.3 million in 2023, then slumped by 47.46% to $3.3 million in 2024.